Licensing Agreements

Affectis Pharmaceuticals in-licenses compound to treat psychiatric disorders

Published in Mental Health Law Weekly, February 24th, 2007

Affectis Pharmaceuticals AG, a biopharmaceutical company developing novel drugs for the treatment of depression and schizophrenia, announced that it has in-licensed a novel, selective Cox-2 inhibitor from Palau Pharma, the R&D subsidiary of Grupo Uriach.

Affectis will develop the compound, named Cimicoxib, as a treatment for depression and schizophrenia. The company expects to start a phase II trial in depression with Cimicoxib this year.

Cimicoxib has already finished phase IIa trials in pain. At present, coxibs are approved for adult rheumatic conditions including osteoarthritis, rheumatoid arthritis and ankylosing spondylitis as well as for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Mental Health Law Weekly

Source: Mental Health Law Weekly (2007-02-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry